Stimulation-evoked Calcitonin Gene-Related Peptide (CGRP) as Biomarker of Migraine

Phase

N/A

Condition

Headaches

Chronic Pain

Pain

Treatment

N/A

Clinical Study ID

NCT05768828

BB 040/22

Ages 18-99
All Genders

Study Summary

This study aims to improve the management migraine by providing a more profound understanding of the interactions of pain disinhibition on the brain stem level and calcitonin gene-related peptide as a main mediator in the generation of migraine headaches. For this purpose, this observational study investigates established neurophysiological and blood biomarkers parameters in association with the clinical phenotype.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Migraine according to ICHD-3 criteria (cases)
No headaches or tension-type headache frequency <1x/year (controls)

Exclusion

Exclusion Criteria:

other chronic pain disorder

Study Design

February 20, 2023

July 30, 2023

Study Description

The study's focus is the investigation of mechanisms that are directly related to the pain generation in migraine. In this context, the primary endpoint is an enhancement of trigeminal stimulation evoked calcitonin gene-related peptide (CGRP). The stimulation is normalized using an established protocol to elicit the nociceptive blink reflex, which is a brain stem reflex to study the trigemino-spinal system. We expect CGRP levels to rise more in patients affected by migraine as compared to controls, based on the observation that painful stimulation elicits migraine attacks. Furthermore, baseline CGRP levels and their association with markers of brainstem excitability are probed.

Connect with a study center

University Medicine Greifswald
Greifswald, 17475
Germany
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.